Risk factors and outcomes of critically ill pregnant COVID-19 patients: Experience from the first and second waves of the pandemic
The Journal of Critical Care Medicine,
Год журнала:
2025,
Номер
11(1), С. 54 - 63
Опубликована: Янв. 1, 2025
Abstract
Introduction
Understanding
the
association
between
risk
factors
and
clinical
outcomes
of
COVID-19
can
lead
to
identifying
suitable
management
strategies
for
reducing
mortality
rate
among
maternal
patients
in
ICU.
Aim
Study
This
study
aims
investigate
associated
with
pregnant
postpartum
women
diagnosed
admitted
intensive
care
unit
(ICU)
May
2020
September
2021.
Materials
Methods
retrospective
cohort
was
conducted
at
Universitas
Indonesia
Hospital.
Secondary
data
collected
from
medical
records
include
all
confirmed
hospital
during
research
period.
Results
The
included
113
found
that
admission
ICU,
age,
gestational
age
significantly
influenced
outcomes,
a
42.11%
ICU-admitted
patients.
Pre-existing
comorbidities
such
as
type-2
diabetes
mellitus,
congestive
heart
failure,
coronary
artery
disease
were
ICU
admission.
Having
least
one
comorbidity
increase
by
six-fold.
Conclusions
emphasizes
importance
monitoring
evaluating
fetal
complications
infection,
highlighting
need
multidisciplinary
involving
intensivists,
obstetricians,
anesthesiologists,
infectious
specialists.
findings
underscore
significance
baseline
health
status
treatment
planning
potential
evidence-based
interventions
improve
pregnancy
preservation.
Further
is
warranted
validate
these
results
enhance
understanding
underlying
pathophysiology.
Язык: Английский
Clinical characteristics of pregnant women with COVID-19 and infection outcomes in one of the largest cities in the Brazilian Amazon
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Окт. 18, 2024
Pregnancy
can
be
a
risk
factor
for
the
development
of
more
severe
COVID-19
with
possible
increase
in
complications
during
pregnancy/birth
and
adverse
neonatal
outcomes.
This
study
aimed
to
describe
analyze
clinical
epidemiological
aspects
SARS-CoV-2
infection
women
perinatal
period
attended
city
Belém,
northern
region
Brazil.
Язык: Английский
Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis
BMC Infectious Diseases,
Год журнала:
2023,
Номер
23(1)
Опубликована: Ноя. 9, 2023
Abstract
Background
Clinical
evidence
suggests
that
pregnant
women
are
more
vulnerable
to
COVID-19,
since
they
at
increased
risk
for
disease
progression
and
obstetric
complications,
such
as
premature
labor,
miscarriage,
preeclampsia,
cesarean
delivery,
fetal
growth
restriction
perinatal
death.
Despite
this
evidence,
often
excluded
from
clinical
trials,
resulting
in
limited
knowledge
on
COVID-19
management.
The
aim
of
systematic
review
meta-analysis
is
provide
better
the
efficacy
safety
available
treatment
women.
Methods
Four
authors
searched
major
electronic
databases
inception
until
1
st
November-2022
controlled
trials/observational
studies,
investigating
outcomes
after
administration
anti-SARS-CoV-2
treatments
affected
by
COVID-19.
analyses
investigated
cumulative
incidence
delivery
maternal
women,
comparing
those
taking
active
medication
vs
standard
care.
Risk
ratios
(RRs)
with
95%
confidence
intervals
were
calculated.
Statistical
significance
was
assessed
using
random
effects
model
inverse-variance
method.
This
conducted
accordance
updated
2020
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA)
guidelines.
protocol
has
been
registered
Prospero
(number
registration:
CRD42023397445).
Results
From
initially
937
non
duplicate
records,
we
full
texts
40
articles,
finally
including
ten
studies.
In
six
1627
patients,
use
casirivimab/imdevimab
(CAS/IMD),
remdesivir,
IFN-alpha
2b
significantly
decreased
need
section
((RR
=
0.665;
95%CI:
0.491–0.899;
p
0.008;
I
2
19.5%;)
(Table
1,
(Fig.
1).
Treatments
did
not
decrease
preterm
admission
neonatal
ICU,
or
stillbirth/perinatal
loss
(
-values
>
0.50
all
these
outcomes)
prevent
towards
severe
degrees
(k
8;
2,374
women;
RR
0.778;
0.550–1.099;
0.15;
0%).
Moreover,
medications
during
pregnancy
modify
death
two
studies
2).
Conclusions
To
our
analysis,
CAS/IMD,
IFN
alpha
reduced
number
sections
but
demonstrated
no
effect
other
related
outcomes.
inability
evaluate
influence
viral
load
illness
development
attributed
lack
data.
review,
side
reported.
Though,
it
essential
medical
community
focus
trials
less
episodic
case
reports
series,
standardization
Язык: Английский
Mendelian Randomization Study: Investigating the Causal Impact of Covid-19 on Adverse Pregnancy Outcomes
Ruisi Tang,
Weijie Guo,
Ying Hu
и другие.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Май 29, 2024
Abstract
Background
Due
to
limitations
in
observational
studies,
the
link
between
COVID-19
and
adverse
pregnancy
outcomes
(APOs)
remains
inconclusive.
This
study
uses
two-sample
Mendelian
randomization
(MR)
analyses
assess
COVID-19's
causal
effects
on
APO
traits.
Methods
We
applied
inverse
variance
weighting
(IVW),
MR-Egger,
weighted
median,
mode,
simple
mode
thoroughly
evaluate
of
infection,
hospitalization,
severity
eight
Results
Our
findings
indicate
that
infection
is
associated
with
an
increased
risk
spontaneous
miscarriages
(OR:
0.95,
95%CI
(0.99,
0.91);
p
=
0.014)
preterm
labor
delivery
1.30,
(1.63,
1.04);
0.019),
a
decreased
eclampsia
0.35,
(0.94,
0.12);
0.033).
Язык: Английский
Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis
Respiratory Investigation,
Год журнала:
2024,
Номер
63(1), С. 20 - 26
Опубликована: Ноя. 29, 2024
Язык: Английский
Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots
International Journal of Neonatal Screening,
Год журнала:
2023,
Номер
9(3), С. 43 - 43
Опубликована: Авг. 2, 2023
To
investigate
COVID-19
surveillance
among
pregnant
women,
the
California
Genetic
Disease
Screening
Program
conducted
a
screening
performance
and
seroprevalence
evaluation
of
maternal
SARS-CoV-2
antibodies
detected
in
banked
newborn
dried
blood
spots
(DBS).
We
obtained
seropositive
results
for
2890
DBS
from
cohorts
2020
2021
using
Enable
Bioscience's
Antibody
Detection
by
Agglutination-PCR
(ADAP)
assay
antibodies.
infer
infection,
we
linked
312
women
with
known
laboratory-confirmed
episode
their
newborn's
SARS-CoV02
antibody
result.
Among
newborns,
453
(15.7%)
DBS.
Monthly
snapshot
statewide
neonates
was
12.2%
(95%
CI
10.3-14.1%,
n
=1156)
December
33.3%
29.1-37.4%,
=
26)
March
2021.
The
longest
time
recorded
infection
to
neonatal
result
11.7
months
mothers
who
had
an
available
PCR
test
Approximately
94%
(153/163)
were
when
occurred
earlier
than
19
days
before
birth.
estimated
relative
sensitivity
identify
prevalent
85.1%,
specificity
98.5%
PPV
99.2%
(n
312);
lowest
during
surge
many
infections
within
Fifty
pre-pandemic
specimens
(100%
seronegative)
23
twin-pair
concordant)
support
intrinsic
ADAP
approaching
100%.
Maternal
is
limited
lag
prior
delivery,
especially
pandemic
surges.
Язык: Английский